Crane Biotherapeutics discovers and develops novel biologic therapies for serious and rare diseases using a proprietary protein engineering platform and cell‑based expression systems. Their integrated preclinical pipeline combines bioinformatics‑driven target selection, in‑vivo disease models, and scalable GMP‑compatible manufacturing to advance high‑affinity biologics toward clinical use for pharmaceutical partners and healthcare providers.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with serious or rare diseases often lack effective treatments, leading to poor health outcomes and limited quality of life.
Solution
Cranebiotherapeutics focuses on discovering and developing novel biotherapeutic candidates to address unmet medical needs. The company leverages advanced protein engineering and cell‑based platforms to create targeted therapies that modulate disease pathways. By integrating preclinical validation with scalable manufacturing processes, Cranebiotherapeutics aims to advance candidates through regulatory milestones toward clinical use. Their approach emphasizes safety, efficacy, and the potential to treat conditions where current options are insufficient.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking innovative biologic therapies for serious or rare diseases.
Features
- Proprietary protein engineering platform for high‑affinity biologics
- Cell‑based expression systems enabling rapid candidate screening
- Integrated preclinical pipeline with in‑vivo disease models
- Scalable GMP‑compatible manufacturing workflow
- Data‑driven target selection using bioinformatics and omics analyses